ClinicalTrials.gg
CompletedNCT02303860Updated May 6, 2015

Pharmacokinetic Study of Multiple Doses of ORM-12741 (Nebula PK 2)

A Phase 1 interventional study of ORM-12741 MR A and ORM-12741 MR B in Healthy, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-06.

Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate ORM-12741 concentrations in blood at steady state.

Read the detailed description

The purpose of this study is to evaluate pharmacokinetic and safety of ORM-12741 after multiple oral dosing of modified release formulations.

02

Conditions studied

  • Healthy

Keywords

  • Healthy volunteer study
03

In context

Lead sponsor

Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written (IC) obtained.
  2. Good general health ascertained by detailed medical history and physical examination.
  3. Females and males between 18 and 65 years of age (inclusive).
  4. (BMI) between 18-30 kg/m2 (inclusive, BMI = weight/height2).
  5. Weight 50-100 kg (inclusive).
  6. Regular intestinal transit (no recent history of recurrent constipation, diarrhoea, or other intestinal problems).

Exclusion criteria

Exclusion Criteria:

  1. Predicted poor compliance or inability to communicate well with the investigator or the study centre personnel.
  2. Veins unsuitable for repeated venipuncture or cannulation.
  3. Evidence of cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator.
  4. Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study. Hormonal and hormone replacement therapy are allowed.
  5. Susceptibility to severe allergic reactions.
  6. Intake of any medication that could affect the outcome of the study, within 2 weeks prior to the first study treatment administration or less than 5 times the half-life of the medication. Possible enzyme inducing drugs will be discussed case-by-case with the sponsor.
  7. Regular consumption of more than 21 units of alcohol per week for males and 16 units per week for females (1 unit = 4 cl spirits, about 13 g of alcohol).
  8. Current use of nicotine-containing products more than 5 cigarettes or equivalent/day.
  9. Inability to refrain from using nicotine-containing products during the stay at the study centre.
  10. Inability to refrain from consuming caffeine-containing beverages during the stay at the study centre, e.g. propensity to develop headaches when refraining from caffeine-containing beverages.
  11. Blood donation or loss of significant amount of blood within 3 months prior to the first study treatment administration.
  12. Any clinically significant 12-lead (ECG) abnormality after 10-minute rest in supine position at the screening visit, as judged by the investigator. For example:

    • (calculated with the Bazett's formula) > 470 msec for females and 450 msec for men.
  13. HR \< 45 beats/minute or > 100 beats/minute after a 10-minute rest in supine position at the screening visit.
  14. At the screening visit systolic blood pressure (BP) \< 90 mmHg or > 150 mmHg after a 10- minute rest in supine position, diastolic BP \< 50 mmHg or > 90 mmHg after a 10-minute rest in supine position, or symptomatic orthostatic hypotension, or

    • decrease of ≥ 20 mmHg of systolic BP or
    • decrease of ≥ 10 mmHg of diastolic BP after 3 minutes in standing position.
  15. Any abnormal value in laboratory tests, or vital signs, or physical examination finding, which in the opinion of the investigator could interfere with the interpretation of the test results or cause a health risk for the subject if he takes part in the study.
  16. History of drug abuse or positive result in drug abuse test.
  17. Positive serology to antibodies (HIVAgAb), virus antibodies (HCVAb) or surface antigen (HBsAg).
  18. Females of if they are not using proper contraception (hormonal contraception, intrauterine device [IUD] or surgical sterilization, spermicidal foam in conjunction with condom on male partner) during the study. Use of oral/hormonal contraception alone is not acceptable. (Note: women of childbearing potential with no current heterosexual relationship can be included without contraception according to the judgement of the investigator).
  19. Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the study subject.
  20. Participation in a clinical drug study within 3 months prior to the first study treatment administration of this study or earlier participation in a clinical study with ORM-12741.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Panel 1

    Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.

    Drug: ORM-12741 MR A · Drug: ORM-12741 MR B · Drug: ORM-12741 IR

  • Experimental
    Panel 2

    Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.

    Drug: ORM-12741 MR A · Drug: ORM-12741 MR B · Drug: ORM-12741 IR

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax, Tmax, AUC, T1/2

    Pharmacokinetics

    Time frame: Blood samples collected once at day 2, 4, 6, 9, 10 and 11; twice on day 8 and frequently on day 7.

Secondary outcomes

  1. Safety - adverse events, vital signs, ECG, safety laboratory values

    Adverse events, vital signs, ECG, safety labs

    Time frame: 8 days per treatment period

07

Study locations

1 site
  • Clinical Research Services Turku - CRST Oy
    Turku, 02520, Finland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2014
First posted
Dec 1, 2014
Start
Oct 2014
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Last update
May 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02303860
Responsible party
Sponsor
First posted
Dec 1, 2014
Start date
Oct 2014
Primary completion
Jan 2015
Completion
Jan 2015
Last update
May 6, 2015

Study contacts

Mika Scheinin, MD
principal investigator · Clinical Research Services Turku - CRST Oy

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ORM-12741

Start the discussion